Pancreatitis Drug Pipeline — PatSnap Eureka
Acute & Chronic Pancreatitis: Trypsin Inhibitors, CFTR Modulators & Anti-Fibrotic Drug Pipeline
No disease-specific pharmacologic therapies are currently approved for acute or chronic pancreatitis. PatSnap Eureka maps the emerging pipeline across three mechanistic pillars — protease inhibition, CFTR modulation, and anti-fibrotic strategies — synthesized from patent and literature evidence.
Pipeline Evidence Stage Distribution
Breakdown of ~75 retrieved results by evidence maturity level
The Pancreatitis Drug Pipeline: Key Therapeutic Modalities
Acute pancreatitis (AP) and chronic pancreatitis (CP) share overlapping pathogenesis but require distinct therapeutic approaches. Retrieved patent and literature evidence clusters around three mechanistic pillars, each targeting distinct nodes in disease progression.
Trypsin Inhibitors & Enteropeptidase Inhibitors
The dominant initiating mechanism in AP is premature intrapancreatic activation of digestive enzyme zymogens — particularly trypsinogen — leading to autodigestion and acinar cell injury. Direct inhibition of trypsin or its activating enzyme enteropeptidase represents the most mechanistically direct intervention. Dabigatran etexilate, an approved oral anticoagulant, competitively inhibits all human and mouse trypsin isoforms with Ki values of 10–79 nM. In the T7K24R trypsinogen mutant mouse model, a single oral gavage produced high-degree histological normalization — the most quantitatively rigorous trypsin inhibitor data in the retrieved dataset.
Preclinical / RepurposingCFTR Modulators & Ductal Dysfunction
CFTR loss-of-function mutations predispose to pancreatitis, but CFTR potentiators can paradoxically restore exocrine function in ways that precipitate ductal obstruction-related pancreatitis. A pediatric case from Athens documented that an adolescent with cystic fibrosis developed pancreatitis after partial recovery of pancreatic exocrine function while receiving ivacaftor. CFTR modulator developers — including those working on ivacaftor and lumacaftor combinations — face a pharmacovigilance challenge that may require combination with secretion-reducing agents such as somatostatin analogues.
Clinical SignalAnti-Fibrotic Approaches for Chronic Pancreatitis
In CP, pancreatic stellate cell (PSC) activation and extracellular matrix remodeling — mediated by TGF-β/Smad2/3, DDR1/DDR2 collagen receptors, and NF-κB — are the primary anti-fibrotic targets. Multiple distinct mechanistic strategies have been identified: DDR1/DDR2 inhibition via imatinib (novel target, preclinical), TGF-β pathway inhibition via galunisertib, targeted liposomal delivery of apigenin, omega-3 DHA supplementation, and CXCR2 antagonism. DDR1/DDR2 inhibition represents a novel anti-fibrotic target not yet widely discussed in the pancreatitis literature.
Preclinical / Novel TargetsBiologic, Kinase Inhibitor & Computational Repurposing
The Johns Hopkins University filed a patent (AU jurisdiction) disclosing TRAIL and anti-DR5 agonistic antibodies for treating pancreatitis pain and fibrosis. NF-κB kinase inhibitors — including PKD inhibitors CID755673 and CRT0066101 from Georgetown University Medical Center — suppress NF-κB activation and attenuate cerulein pancreatitis severity. A computational network medicine study from Mission:Cure identified resiniferatoxin among leading CP drug candidates, applying a literature-derived knowledge graph and machine learning to predict approved drugs for CP.
Patent + ComputationalKey Molecular Targets & Candidate Evidence Strength
Synthesized from patent and literature records retrieved across targeted searches on AP and CP drug development.
Molecular Target Recurrence Across Retrieved Results
PRSS1/Trypsinogen and NF-κB appear most frequently across the ~75 retrieved records, reflecting their central role in both AP and CP pathogenesis.
Dabigatran Ki Values vs Trypsin Isoforms (UCLA, 2022)
Inhibition constants in the 10–79 nM range across all human and mouse trypsin isoforms confirm pharmacological tractability at oral doses for pancreatitis repurposing.
Anti-Fibrotic Approaches for Chronic Pancreatitis — Evidence Stage by Mechanism
Six distinct anti-fibrotic mechanistic strategies identified in retrieved CP literature, spanning from novel computational predictions to preclinical proof-of-concept studies.
From PRSS1 to ER Stress: The Convergent Pathogenesis of AP and CP
The retrieved dataset converges on a multi-pathway disease model. In AP, the dominant initiating mechanism is premature intrapancreatic activation of digestive enzyme zymogens — particularly trypsinogen — leading to autodigestion, acinar cell injury, and systemic inflammatory cascades. However, retrieved results also emphasize that "the widely-accepted autodigestion theory of AP is now facing challenges, since inhibiting protease activation has negligible effectiveness for AP treatment despite numerous efforts," with malfunction of the unfolded protein response (UPR) increasingly implicated as a co-driver of pathogenesis.
PRSS1 (cationic trypsinogen / serine protease 1) is the most recurrently cited molecular target in the retrieved dataset, featuring in studies from UCLA, Southern Medical University, and the University of Pittsburgh. Mutations in PRSS1 are highlighted as a central genetic risk factor for both AP and CP. PRSS1 transgenic mouse models were used extensively across retrieved studies to probe disease progression. Retrieved data also note that integrated traditional Chinese medicine can regulate PRSS1 and SPINK1 expression in AP patients, with clinical evidence reported in a study of 100 patients.
ER stress and UPR pathways — including ATF6, XBP1, CHOP/DDIT3, and the PERK pathway — are identified as mechanistic nodes in acinar cell injury and CP progression. Notably, global deletion of DDIT3/Chop in CPA1 N256K mice did not ameliorate chronic pancreatitis, suggesting CHOP-independent apoptotic mechanisms are operative and that targeting CHOP alone may be insufficient. This signals that combination approaches addressing both upstream protease activation and downstream ER stress may be required. For more on genetic pancreatitis targets, see the OMIM database and PatSnap's life sciences intelligence platform.
The NLRP3 inflammasome is described across multiple retrieved results as a central driver of sterile pancreatic inflammation in both AP and CP. Compounds including iguratimod T-614, cashew nut components, and AICAR are shown to suppress NLRP3 activation. CXCR2 drives neutrophil recruitment in both acute and chronic pancreatic inflammation, with Cxcr2-knockout mice showing strong protection from tissue damage — positioning CXCR2 antagonists as a dual modality capable of addressing both acute inflammatory injury and chronic fibrotic progression.
Pipeline Strategy & Translational Signals
Key strategic implications derived from the retrieved patent and literature dataset for drug developers, IP teams, and research organizations.
Dabigatran: IND-Enabling Evidence for Trypsin-Dependent Pancreatitis
With Ki values of 10–79 nM against all human trypsin isoforms, oral bioavailability, and an established human safety profile, a Phase II trial in trypsin-dependent genetic pancreatitis (PRSS1 mutation carriers) is mechanistically justified by the UCLA data. IP freedom-to-operate analysis is advisable, as no composition-of-matter patent for this indication was retrieved.
CFTR Modulator Pharmacovigilance: A Paradoxical Challenge
Restoration of exocrine function in pancreatic-insufficient CF patients may unmask pancreatitis risk, as evidenced by the ivacaftor case from Athens and the CFTR-mutation drug-induced pancreatitis case from Geneva. Clinical monitoring protocols and potentially combination with somatostatin analogues may be warranted in patients transitioning from pancreatic insufficiency to partial sufficiency on modulators.
Who Is Driving Pancreatitis Drug Research?
The retrieved dataset is overwhelmingly literature-driven — 2 patents vs approximately 75 academic papers — suggesting the field remains in a predominantly academic/preclinical research phase with limited commercial IP consolidation.
| Institution | Country | Key Contribution | Modality | Stage |
|---|---|---|---|---|
| University of California, Los Angeles | USA | Dabigatran Ki values (10–79 nM) vs all trypsin isoforms; T7K24R mouse model efficacy | Small molecule repurposing | Preclinical |
| Southern Medical University, Guangzhou | China | PRSS1 transgenic models, St13/arachidonic acid pathway, ATP8b1/efferocytosis mechanism | Target discovery | Preclinical |
| University of Glasgow | UK | CXCR2 inhibition — dual AP/CP protection in Cxcr2-KO mice; neutrophil depletion studies | Chemokine receptor antagonism | Preclinical |
| The Johns Hopkins University | USA | TRAIL/anti-DR5 agonistic antibodies for pancreatitis pain and fibrosis (AU patent, active) | Biologic / antibody | Patent (AU) |
| NIPER (Natl. Inst. Pharmaceutical Education & Research) | India | First identification of DDR1/DDR2 upregulation in CP; imatinib anti-fibrotic proof-of-concept | Tyrosine kinase inhibitor repurposing | Preclinical |
| Mission:Cure / Pistoia Alliance | USA | Network medicine / knowledge graph ML approach; resiniferatoxin as top CP candidate | Computational repurposing | Computational |
Track Every Pancreatitis Assignee & Filing in Real Time
PatSnap Eureka monitors patent filings, literature publications, and clinical signals across all pancreatitis-relevant institutions globally. Explore PatSnap's IP analytics platform for landscape analysis.
Limited but Actionable: Clinical Signals in the Retrieved Dataset
The retrieved dataset contains limited but noteworthy clinical signals. No retrieved results document completed Phase II or Phase III trials for any of the three focal modalities — trypsin inhibitors, CFTR modulators, or anti-fibrotics — in pancreatitis. Retrieved results explicitly state that "no drugs now exist to meet this need" for CP and that "disease-specific effective remedy remains obscure" for AP.
Fenofibrate + octreotide (clinical, hypertriglyceridemia-AP): Retrieved results from Shanghai Tenth People's Hospital report clinical data demonstrating that fenofibrate combined with octreotide acetate exerts synergistic NF-κB P65 inhibitory effects and provides superior outcomes versus octreotide alone in hypertriglyceridemia-AP patients. This is the most clinically advanced combination signal in the retrieved dataset and represents evidence-based combination data from human patients.
ITCM and PRSS1/SPINK1 downregulation (clinical, n=100): A randomized clinical study in 100 AP patients reported that external herbal integrated traditional Chinese medicine preparation significantly improved outcomes with measurable PRSS1 and SPINK1 modulation at both mRNA and protein levels compared to placebo — one of the few retrieved results with prospective human interventional data.
Antioxidant meta-analysis (CP, n=352): A systematic review included four RCTs with 352 CP participants evaluating antioxidants for pain. The retrieved result reports no significant pain reduction versus placebo, providing negative clinical evidence that discourages antioxidant monotherapy for pain as a primary endpoint. This is important context for trial design. For broader clinical context on pancreatitis management, see NIH PubMed and the WHO's gastrointestinal disease resources. Explore how life sciences teams use PatSnap to accelerate drug discovery.
Acute & Chronic Pancreatitis Drug Pipeline — Key Questions Answered
Dabigatran etexilate repurposing for trypsin-dependent pancreatitis represents the most translationably mature asset in the retrieved dataset: with Ki values of 10–79 nM against all human trypsin isoforms, oral bioavailability, and an established human safety profile, a Phase II trial in trypsin-dependent genetic pancreatitis (PRSS1 mutation carriers) is mechanistically justified by the UCLA data.
CFTR modulator developers face a paradoxical pharmacovigilance challenge: restoration of exocrine function in pancreatic-insufficient CF patients may unmask pancreatitis risk, as evidenced by the ivacaftor case from Athens. Clinical monitoring protocols and potentially combination with secretion-reducing agents (somatostatin analogues) may be warranted in patients transitioning from pancreatic insufficiency to partial sufficiency on modulators.
Retrieved results from the National Institute of Pharmaceutical Education and Research describe, for the first time, the role of DDR1 and DDR2 (collagen receptors/receptor tyrosine kinases) in cerulein-induced CP. Pancreatic stellate cells and CP mice showed significant upregulation of DDR1 and DDR2. The selective DDR1/DDR2 inhibitor imatinib demonstrated protective anti-fibrotic effects in CP mice.
No. Retrieved results explicitly state that no drugs now exist to meet this need for CP and that disease-specific effective remedy remains obscure for AP. Supportive care remains the standard of treatment, and no retrieved results document completed Phase II or Phase III trials for trypsin inhibitors, CFTR modulators, or anti-fibrotics in pancreatitis.
Retrieved results from the University of Pittsburgh propose a sentinel acute pancreatitis event (SAPE) framework in which the first AP episode sensitizes the pancreas to recurrent AP and ultimately CP. This model signals that early therapeutic intervention at the first AP event — potentially combining trypsin inhibitors, anti-inflammatory agents, and genetic risk assessment including CFTR and PRSS1 screening — could prevent progression to CP, representing a disease-interception rather than disease-treatment paradigm.
Retrieved clinical data from Shanghai Tenth People's Hospital signal that combining fenofibrate (PPARα agonist) with octreotide acetate is more effective than monotherapy in the hypertriglyceridemia-AP subtype, demonstrating synergistic NF-κB P65 inhibitory effects. This is the most clinically advanced combination signal in the retrieved dataset.
Still have questions about the pancreatitis pipeline? Let PatSnap Eureka answer them for you.
Ask Eureka About Pancreatitis TargetsAccelerate Your Pancreatitis Drug Discovery with AI-Powered Innovation Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, identify repurposing opportunities, and track emerging IP across rare and underserved disease areas.
References
- Preclinical testing of dabigatran in trypsin-dependent pancreatitis — Department of Surgery, University of California Los Angeles, 2022
- Role of SCO-792, A Novel Enteropeptidase Inhibitor, In the Prevention of Post-ERCP Pancreatitis — California Institute of Behavioral Neurosciences & Psychology, 2021
- Integrated traditional Chinese medicine improves acute pancreatitis via the downregulation of PRSS1 and SPINK1 — Department of Gastroenterology, First Hospital of Tianjin, 2015
- Role of proteases and antiprotease in the etiology of chronic pancreatitis — Division of Biostatistics, National Institute of Nutrition, Hyderabad, 2012
- Recurrent Acute Pancreatitis and Therapy for Ulcerative Colitis — Service of Gastroenterology, Geneva University Hospital, 2010
- Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor — Cystic Fibrosis Department, Agia Sophia Children's Hospital, Athens, 2020
- Caerulein-induced acute pancreatitis in mice that constitutively overexpress Reg/PAP genes — University of Kansas School of Medicine, 2006
- Inhibition of DDR1 and DDR2 receptors: Potential Therapeutic Option to Treat Pancreatic Fibrosis in Experimental Chronic Pancreatitis Model — National Institute of Pharmaceutical Education and Research, 2021
- Galunisertib (LY2157299), a TGF-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats — Department of Clinical Laboratory, Women and Children's Hospital of Qingdao, 2016
- Identification of Novel Ligands for Targeted Antifibrotic Therapy of Chronic Pancreatitis — Department of Biomedical Engineering, University of Virginia, 2021
- Docosahexaenoic Acid Inhibits Expression of Fibrotic Mediators in Mice With Chronic Pancreatitis — Department of Food and Nutrition, Yonsei University, 2020
- CXCR2 inhibition suppresses acute and chronic pancreatic inflammation — Institute of Cancer Sciences, University of Glasgow, 2015
- A Network Medicine Approach to Drug Repurposing for Chronic Pancreatitis — Mission:Cure, Elsevier, Pistoia Alliance, 2020
- Compositions and methods for treating pancreatitis and pain with death receptor agonists — The Johns Hopkins University, 2020 [Patent, AU]
- Novel Small Molecule Inhibitors of Protein Kinase D Suppress NF-kappaB Activation and Attenuate the Severity of Rat Cerulein Pancreatitis — Georgetown University Medical Center, 2017
- Inhibition of PAK1 alleviates cerulein-induced acute pancreatitis via p38 and NF-κB pathways — Department of Emergency, Changzhou City No.1 People's Hospital, 2019
- PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis — Department of Gastroenterology, Shanghai Tenth People's Hospital, 2021
- Central role of the sentinel acute pancreatitis event (SAPE) model in understanding recurrent acute pancreatitis: Implications for precision medicine — University of Pittsburgh and UPMC, 2022
- Means for the prophylaxis and treatment of acute and chronic pancreatitis — Limited Liability Company Gamavetfarm, 2019 [Patent, EP]
- NIH PubMed — National Library of Medicine
- World Health Organization — Gastrointestinal Disease Resources
- OMIM — Online Mendelian Inheritance in Man (PRSS1, SPINK1, CFTR gene entries)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.